<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03228030</url>
  </required_header>
  <id_info>
    <org_study_id>15-387</org_study_id>
    <nct_id>NCT03228030</nct_id>
  </id_info>
  <brief_title>Thiamine Supplementation in Heart Failure: a Pilot Randomized Controlled Crossover Trial</brief_title>
  <acronym>THIAMINE-HF</acronym>
  <official_title>Thiamine Supplementation in Heart Failure: a Pilot Randomized Controlled Crossover Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McMaster/St. Peter's Hospital Chair of Aging</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure (HF) is a major cardiovascular disease with increasing prevalence. Thiamine
      deficiency is common in HF patients. Previous small studies have shown that thiamine
      supplementation can improve left ventricular systolic function in HF, but larger clinical
      studies are lacking. Given the ease of supplementation and the potential benefits in HF, we
      aim to conduct a pilot randomized controlled trial (RCT) using high dose thiamine
      supplementation in HF patients. The main goal of this pilot study is to determine the
      feasibility of recruitment for an RCT of thiamine supplementation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2018</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment</measure>
    <time_frame>11 months</time_frame>
    <description>Number of participants recruited during the study period. This is a feasibility outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Refusal rate</measure>
    <time_frame>11 months</time_frame>
    <description>Number of eligible individuals refusing to participate in the research study. This is a feasibility outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retention rate</measure>
    <time_frame>11 months</time_frame>
    <description>Number of participants completing the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance rate</measure>
    <time_frame>11 months</time_frame>
    <description>Proportion of participants with &gt;80% adherence to intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction (LVEF)</measure>
    <time_frame>3 months</time_frame>
    <description>Echocardiogram measurement of left ventricular ejection fraction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak global longitudinal strain (%)</measure>
    <time_frame>3 months</time_frame>
    <description>Speckle tracking echocardiogram measurement of heart contractility. This is a more sensitive measurement of heart function than LVEF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP</measure>
    <time_frame>3 months</time_frame>
    <description>Heart failure biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) class</measure>
    <time_frame>3 months</time_frame>
    <description>Heart function symptom grading</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>Kansas City Cardiomyopathy Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HF hospitalizations</measure>
    <time_frame>7.5 months</time_frame>
    <description>Number of hospital stays &gt;24h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HF emergency room visits</measure>
    <time_frame>7.5 months</time_frame>
    <description>Number of hospital visits &lt;24h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death due to cardiovascular causes</measure>
    <time_frame>7.5 months</time_frame>
    <description>As adjudicated by study committee</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Heart Failure</condition>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <condition>Thiamine Deficiency</condition>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Thiamine mononitrate 500mg po daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 months on thiamine, followed by 6 week washout period, and then 3 months on placebo arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 months on placebo, followed by 6 week washout period, and then 3 months on thiamine</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Thiamine</intervention_name>
    <description>Capsules</description>
    <arm_group_label>Thiamine mononitrate 500mg po daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥60

          -  NYHA class II-IV symptoms

          -  Recent HF-related admission in past 12 months

          -  LVEF ≤45% on 2D/3D echocardiography or radionuclide angiography (RNA) in the past 12
             months (on optimal therapy)

          -  Medically optimized prior to enrolment with angiotensin converting enzyme inhibitor or
             angiotensin receptor blocker (± neprilysin inhibitor), β-blocker, and/or aldosterone
             antagonist at target or maximally tolerated doses.

          -  Patients must be stable on medications without hospitalization in the past month.

        Exclusion Criteria:

          -  Taking &gt;2.5mg/d of thiamine supplement. Allows standard multivitamin. B complex
             vitamin not allowed due to high thiamine content.

          -  Unable to swallow study medication. A placebo swallowing test will take place at
             screening.

          -  Clinical indication for thiamine supplementation including symptomatic thiamine
             deficiency (Wernicke's encephalopathy, severe malnutrition, refeeding syndrome) and
             heavy alcohol use, &gt;15 standard drinks per week in men and &gt;10 standard drinks per
             week in women.

          -  End-stage renal disease on dialysis

          -  Severe mitral valve disease because this impacts the accuracy of speckle tracking
             analysis on echocardiography.

          -  Non-English speaking (unable to complete questionnaires).

          -  Unable to provide written consent.

          -  Cognitive impairment without a caregiver administering medications.

          -  Expected survival &lt;1 year due to non-cardiac disease.

          -  Expected heart transplantation in &lt;6 months (± left ventricular assistive device).

          -  Allergies to the ingredients of the study medication or placebo
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric KC Wong, MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine Demers, MD MSc FRCPC</last_name>
    <phone>905-521-2100</phone>
    <phone_ext>73324</phone_ext>
    <email>demers@hhsc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Demers, MD, MSc, FRCPC</last_name>
      <phone>905-521-2100</phone>
      <phone_ext>73324</phone_ext>
      <email>demers@hhsc.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2017</study_first_submitted>
  <study_first_submitted_qc>July 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>thiamine</keyword>
  <keyword>heart failure</keyword>
  <keyword>heart failure with reduced ejection fraction</keyword>
  <keyword>geriatric</keyword>
  <keyword>thiamin</keyword>
  <keyword>vitamin b1</keyword>
  <keyword>congestive heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Thiamine Deficiency</mesh_term>
    <mesh_term>Beriberi</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thiamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

